



Bilcare Clinical Services in India pioneers the biotech vaccine supplies for a global clinical trial.

- DMF regd. with USFDA
- EEC / USP
- Member, IQA, London
- OPPI Award Winner
- Pioneer Status from Govt. of Singapore
- ISO 9001:2000 & 14001:2004 Company

Bilcare, an unique organization with a strong research foundation and an unending quest for global leadership. An organization, integrated with global Pharmaceuticals having best in class manufacturing and research facilities spread worldwide. An organization made up of motivated people who go that extra mile to spread excellence and joy.

INDIA : USA : SINGAPORE : GERMANY : BRAZIL : CHINA : UK

Bilcare Limited - Regd. Office : 1028, Shirol, Pune 410 505.

Unaudited Financial Results for the quarter and half year ended 30th September, 2007

(Rs. in Crores)

Sr. No.	Particulars	Quarter Ended 30th Sept. 2007 (Unaudited)	Corresponding Quarter Ended 30th Sept. 2006 (Unaudited)	Six Months Ended 30th Sept. 2007 (Unaudited)	Corresponding Six Months Ended 30th Sept. 2006 (Unaudited)	Previous Year Ended 31st March 2007 (Audited)	Consolidated Quarter Ended 30th Sept. 2007 (Unaudited)	Consolidated Six Months Ended 30th Sept. 2007 (Unaudited)	Consolidated Previous Year Ended 31st March 2007 (Audited)
1.	Net Sales/Income from Operations	97.95	78.01	190.83	150.88	322.98	137.79	268.62	407.86
2.	Other Income	4.33	0.53	5.15	0.85	18.46	4.93	5.96	17.87
3.	Total Expenditure								
	a) (Increase)/Decrease in Stock in Trade	(1.03)	(3.80)	(13.05)	(1.01)	(1.95)	0.17	(13.33)	(5.15)
	b) Consumption of Raw Materials	59.60	52.09	126.25	95.18	198.92	76.07	162.16	248.39
	c) Staff Cost	3.90	3.10	7.69	5.08	12.00	14.98	28.65	22.39
	d) Other Expenditure	8.78	5.19	17.23	10.10	23.98	15.48	29.04	43.11
4.	Interest	2.72	1.84	5.49	3.30	7.96	2.98	6.09	9.12
5.	Depreciation	3.55	2.21	7.10	4.41	10.72	4.75	9.80	15.44
6.	Profit before tax	24.76	17.91	45.27	34.67	89.81	28.29	52.17	92.43
7.	Provision for taxation	8.42	6.09	15.39	11.73	31.25	9.22	16.57	32.51
8.	Net Profit	16.34	11.82	29.88	22.94	58.56	19.07	35.60	59.92
9.	Paid-up Equity Share Capital (face value Rs.10/- each)	15.25	14.20	15.25	14.20	14.20			
10.	Reserves excluding Revaluation Reserves					184.33			189.70
11.	EPS for the Period (Rs.)								
	- Basic	10.71	8.32	18.65	16.15	41.24			
	- Diluted	9.75	7.83	17.05	15.20	35.29			
12.	Public Shareholding								
	- No. of Shares	8668430	7754526	8668430	7754526	7619526			
	- Percentage of Shareholding	56.84%	54.61%	56.84%	54.61%	53.66%			

Notes :

1. The Company's main business segment is advanced pharma packaging solutions.
2. The Company had received 1 investor complaint during the quarter, which was redressed and there were no investor complaints pending for redressal at the commencement and at the end of the quarter.
3. The Company has, during the quarter, allotted 155,904 Equity Shares of Rs.10/- each upon partial conversion of the Foreign Currency Convertible Bonds (FCCBs) issued earlier at a conversion price of Rs. 880 per share including premium. Consequently, the Paid-up Equity Share Capital of the Company stands increased to Rs. 152,497,040/-.
4. The previous year's figures have been regrouped / readjusted wherever necessary.
5. The above unaudited Financial Results were approved by the Board of Directors of the Company at its meeting held on 30th October, 2007.
6. The Company has started providing Consolidated results from the current year and hence figures for the corresponding quarter of the previous year are not available.

Pune : October 30, 2007

For Bilcare Limited
Mohan H. Bhandari
Managing Director

Size : 33cm X 21cm